Neurodegenerative disorders include a group of severe diseases that share a core including a gradual loss of previously acquired motor, sensory and cognitive functions. In pediatric age, the main diagnostic issues are the discrimination between the loss of previously acquired competencies and the lack of achievement of specific developmental milestones. An ideal classification of these disorders could be based on the combination of genetic, clinical and neuroimaging features. Diagnostic workup should be organized with a special attention to the few diseases with an available and effective therapeutic treatment. The present paper reports a proposal of classification that is based on the prominently involved structure and summarizes the hallmarks for clinical approach and therapeutic management.
Background
Neurodegenerative disorders include a group of severe diseases in which a progressive loss of neuronal structures or functions in different areas of central and peripheral nervous system is present [1] . The core clinical features of these disorders can be summarized as the gradual loss of previously acquired motor, sensory and cognitive functions [1] .
These patterns are relatively easy to asses in adult neurology where Alzheimer and Parkinson diseases are largely prominent under the epidemiological viewpoint [1] . More challenging differential diagnostic difficulties can be experienced in pediatric age because: (a) the underlying diseases are rare and predominantly genetic with only a few specialized clinical centres having expertise; (b) pathogenetic mechanisms and clinical presentations are wider and more heterogeneous; (c) the discrimination between the loss of a previously acquired cerebral function and the delay in the achievement of specific developmental milestones can be extremely hard [2] .
This review aimed to summarize the current principle of clinical management of this expanding group of diseases that is often underdiagnosed.
Classification
No optimal and agreed classification is available for childhood onset neurodegenerative disorders because pathogenic mechanisms and molecular genetics basis are not completely known for different clinical entities despite the ever increasing evidences emerging in the last decade. A useful and pragmatical classification should take into account that these conditions involve different cortical or subcortical structures, cellular or sub-cellular networks and disease-causing genes [2] . Even if all pediatric neurodegenerative disorders do not present with structural abnormalities at MRI, neuroimaging remains a valuable support [2] . The grouping of different diseases within possible classification systems is often arbitrary because of the frequent involvement of multiple cerebral sites in the pathogenic mechanisms and the existence of overlapping clinical and neuroradiological features. A possible criterium for classification, that takes into account both anatomic sites in which structural or functional impairment is prominent and pathogenic mechanisms (including molecular genetic basis where it is possible), is suggested in Table 1 . 
Diagnostic approach
The first step in the diagnostic workup of patients with suspected neurodegenerative disorders is the correct characterization of the progressive regression of neurological functions [2] . Different neurodevelopmental (i.e., ADHD, autism spectrum disorders) and psychiatric disorders (i.e., depression) may simulate a neurodegenerative disease [2] . After having assessed the loss of previously acquired competencies, physicians should evaluate the nature of the possible etiology (genetically determined or acquired?) and the cerebral structure that is prominently impaired [2] . A possible diagnostic algorithm is suggested in Fig. 1 . Some examples of neuroradiological patterns are illustrated in Fig. 2 . The steps of this algorithm should be considered after having taken into account that in most of the neurodegenerative disorders multiple cerebral sites are contemporarily involved and overlapping clinical features are common. A small number of symptoms (including seizures, intellectual deterioration, feeding difficulties, loss of motor skills, vision, hearing and speech) represent core features of different diseases and the same disease could have variable clinical presentations, degrees of severity and course of illness in the different age ranges [3] . Usually, the later the first sign appears, the slower does the disease progress [3] . Eventually, precipitating factors should be adequately considered because in some cases an acute event highlights underlying disorders with genetic basis (i.e., head trauma in subjects with vanishing white matter disease) [3] . The involvement of organs other than those in CNS should always be searched with particular attention paid to ophthalmic abnormalities, organomegalies, endocrine dysfunctions, facial dysmorphisms and micro or macrocephaly [4] .
Genetically determined disorders

Leukoencephalopathies
The term "leukoencephalopathies" identifies all the inherited disorders involving white matter and it is more correct than the more known and popular term of "leukodystrophies" [5] . The incidence of these disorders varies between 1:7663 and 1:50,000 and a mortality up to 34% (and a mean age at death of 8.2 years) was reported [6, 7] . Recent research developments highlighted the pathogenic relevance of cell types other than oligodendrocytes and structures other than myelin driving white matter pathology (i.e., astrocytes, neurons, microglia and blood vessels) [5] . Van Der Knaap and Brugiani summarized these data in a novel proposal of classification that is enclosed in Table 1 [5] . The spectrum of disease-causing genes that was identified in the last decade became enlarged for all the new proposed classes. [5] . In this context, an essential molecular genetic workup (through single gene sequencing or oriented gene panels) should include the following genes: (a) PLP1, GJC2, AIMP1, HSPD1, FAM126A, POLR3A, POLR3B, RARS, PYCR2, POLR1C, and VPS11 for hypomyelinating disorders [8] ; (b) ARSA, GALC, PSAP, ABCD1 and SUMF1 for demyelinating disorders [5] ; (c) ASPA, Cx32, PAH and several mitochondrial genes for vacuolating disorders of myelination [5] ; (d) TUBB4, AGC1, AIMP1, HSPD1, POLR3A, POLR3B, HBSL, GLB1 for leukoaxonopathies [5] ; (e) CSF1R for microgliopathies [5] ; and (f) SNORD118 for leukovasculopathies [5] .
Clinical suspect of a leukoencephalopathy should be strongly considered when motor impairment represents the major sign/symptom at the onset (seizures or cognitive regression are more frequently the initial presentations of disorders with a primary involvement of cerebral gray matter) [6] . A real motor deterioration is not frequent in hypomyelinating disorders in which the acquisition of motor developmental milestones is generally delayed [6, 8] . Seizures occur early in the course of a restricted number of leukoencephalopathies (i.e., Alexander disease, Krabbe disease, Canavan disease and Leukoencephalopathy with thalamus and brainstem involvement and high lactate) [6] . Among extra-neurological symptoms, ophthalmologic and endocrine abnormalities are more informative in selected cases (i.e., cataracts in cerebrotendinous xanthomatosis, optic atrophy in Canavan disease, adrenal insufficiency in adrenoleukodystrophy or hypothyroidism in Aicardi-Goutieres syndrome) [6] . MRI patterns of white matter abnormalities, that can be useful for the differential diagnosis, include the presence of hypomyelination (two consecutive scans are necessary to assess the lacking progression of myelination), the presence of confluent lesions (isolated or multifocal lesions are usually associated with acquired disorders), the anatomic localization of the alterations (i.e., frontal in Alexander disease, parieto-occipital in X-linked adrenoleukodystrophy, subcortical in Canavan disease) and the 1HMRS traces (NAA increase in Canavan disease, lactate detection in several mitochondrial disorders) [6] .
Disorders with prominent involvement of cerebral gray matter
Epileptic and developmental encephalopathies
Patients in which clinical pattern is dominated by early onset epileptic seizures causing a progressive loss of cognitive and motor functions should be suspected to have an epileptic encephalopathy (also including progressive myoclonus epilepsies) [9] . These diseases have all the features included in the concept of neurodegenerative disorders when neurodegeneration is clearly produced by epilepsy evolution [10] . To date in the OMIM database, 62 monogenic diseases are listed as "early infantile epileptic encephalopathies" caused by mutations of genes encoding for neuronal ion channels, proteins involved in synaptic transmission or interneurons functions [10] . Most of these forms are not neurodegenerative disorders but they should be considered
IS IT A REAL NEURODEGENERATIVE DISORDER?
Proved regression in gross/fine motor, speech/language, cognitive, social/personal and daily living activities or in sensorial functions (including vision and hearing)
IS IT A GENETICALLY DETERMINED OR AN ACQUIRED DISORDER? OTHER NON NEUROLOGICAL SYMPTOMS ? WHAT NEUROLOGICAL SYMPTOMS ARE PROMINENT?
SYMPTOMS OF CORTICAL DYSFUNTIONS (see Table 1 as "developmental encephalopathies including epilepsy" because their evolution includes delayed intellectual, motor and sensorial milestones resulting from the specific gene defects and not by seizures effects [11] . Next-generation sequencing panels have increased the diagnosis of epileptic and developmental encephalopathies (detection rate for pathogenic/likely pathogenic mutations between 18.3 and 40% according to the different published series) and highlighted the prominent role of mutations of SCN1A, CDKL5, SCN2A, and STXBP1 in terms of incidence [12, 13] .
Lysosomal storage diseases
The association of developmental slowing/regression with progressive visual loss, cognitive impairment, epilepsy and motor deterioration should be used as referring symptoms for those suspected to have a neuronal ceroid lipofuscinosis [14] . This group includes 14 clinical forms with different age at the onset (congenital presentation in CLN 10, early infantile onset in CLN1 and CLN14, late infantile onset in CLN1, CLN2,CLN5, CLN6 and CLN7, juvenile presentation in CLN1 and CLN3 and adult onset in CLN1, CLN4, CLN6 and CLN13) [14] . Diagnostic workup includes the demonstration of peculiar patterns at light and electron microscopic evaluation of patients' lymphocytes or fibroblast (granular osmiophilic deposits in CLN1 disease and CLN10/CTSD forms, curvilinear profiles in CLN2 disease, fingerprint profiles in CLN3 disease, mixed-type inclusions in CLN5, CLN6, MFSD8, CLN8, and other late-infantile and adult variants) and of pathogenic mutations (13 forms are associated with a known causative gene including PPT1, TPP1, CLN3, DNAJC5, CLN5, CLN6, MFSD8, CLN8, CTSD, GRN, ATP13A2, CTSF or KCTD7) [14] . Niemann-Pick type C disease is a rare (estimated incidence of 1:100.000 patients) disorder of intracellular trafficking of lipids whose clinical spectrum varies between a neonatal form and a chronic neurodegenerative adult onset disease with the possible involvement of all the age ranges [15] . Core symptoms are represented by unexplained neonatal jaundice, splenomegaly, cognitive regression (up to dementia), vertical supranuclear gaze palsy affecting saccades, epilepsy, dysphagia and psychiatric manifestations [15] . Filipin test on fibroblast (a strictly dependent operator sensitive test) and molecular genetics represent the gold standards for the diagnosis even when the dosage of plasma oxysterols gained a significant credit as a biomarker in the last years [15] . 
Mitochondrial diseases
A possible mitochondrial-related neurodegeneration should be suspected when signs of encephalopathy and neurocognitive regression are associated with ocular, muscular and liver impairment (less frequently other organs including heart or kidney), lactic acidosis or a demonstrated maternal inheritance [16] . MRI abnormalities that can be observed in the disorders involving cerebral gray matter include diffuse cortical and subcortical atrophy, NAA reduction at 1HMRS or occipital T2-hyperintensities (i.e., Alpers disease) or strokelike lesions beyond vascular territories (i.e., MELAS) [16, 17] .
Alsin-related disorders
Patients with signs of progressive retrograde degeneration of upper motor neuron and corticospinal tracts should be screened for mutation of ALS2 gene within three distinct possible phenotypes with different age at onset: infantile ascending hereditary spastic paraplegia, juvenile primary lateral sclerosis and autosomal recessive juvenile amyotrophic lateral sclerosis [18] .
Hereditary spastic paraplegia
Hereditary spastic paraplegia is a heterogeneous group of disorders presenting with progressive spasticity and weakness of the lower limbs resulting from the length-dependent distal axonal degeneration of the corticospinal tracts [19] . These disorders can be transmitted with variable modes of inheritance (autosomal dominant, autosomal recessive, and X-linked) and 72 disease-loci and 55 disease-causing genes (identified as SPG = spastic paraplegia genes) have been reported [20] .
Disorders with prominent involvement of basal ganglia
Neurodegeneration with brain iron accumulation disorders
Neurodegeneration with brain iron accumulation (NBIA) includes a clinically and genetically heterogeneous group of disorders (nine disease-causing genes were reported) that share the feature of an abnormal storage of iron in the basal ganglia [21] . The most common NBIA disorders include pantothenate kinase deficiency, phospholipase A2 deficiency, C19orf12-related mitochondrial membrane protein-associated neurodegeneration and WDR45-related beta-propeller protein-associated neurodegeneration [22] . Other rarest disorders result from mutations in the genes CoASY, ATP13A2, and FA2H [22] . Clinical presentation is variable and include psychomotor regression, spasticity or extrapyramidal rigidity, dystonia, early onset parkinsonism, ocular abnormalities (i.e., pigmentary retinopathy in pantothenate kinase deficiency, optic atrophy in phospholipase A2 deficiency and in fatty acid-2 hydroxylase-associated neurodegeneration) or possible autistic features [21] . MRI abnormalities include hypointense (but also hyperintense) lesions mainly involving globus pallidus and substantia nigra but also other basal ganglia, cerebellar peduncles and dentate [21, 22] .
Monogenic heredodegenerative dystonia
To date, 28 different DYT loci were reported as having a pathogenic relationship with monogenic dystonia (including isolated forms, dystonia-plus syndromes in which dystonia is associated with parkinsonism or myoclonus and dystonia associated with other neurological symptoms) [23] . Most of the forms with a progressive course after a pediatric onset have an autosomal dominant mode of inheritance and a clinical stabilization in early adulthood is possible in some cases [23] . Patients who are suspected to have one of these disorders are strongly candidate for next-generation sequencing characterization during the diagnostic workup because of the extensive overlapping of clinical features among the different forms [23] .
Inherited choreic disorders
A progressive cognitive deterioration associated with dystonia parkinsonism with onset during adolescence is the main pre-motor manifestation of Huntington disease while chorea usually appears in early adulthood [24] . Onset of motor symptoms occurs earlier in subjects with more extended triplet repetition [24] . A recent voxel-based morphometry study demonstrated a correlation between striatal loss and the degree of motor and oculomotor impairment in premotor phases [24] .
Other disorders associated with chorea include VPS13A-related choreo-acanthocytosis (presenting with dystonia, seizures, muscle weakness, psychiatric manifestation after adolescence, increased quote of acanthocytes at peripheral blood smear and iperCKemia) and infantile bilateral striatal necrosis (presenting with a gradual loss of motor and verbal skills up to a complete lack of language and a quadriparesis, generalized seizures, myoclonus and basal ganglia atrophy at MRI) [25, 26] .
Metabolic disorders
Leigh syndrome is a severe disorder (with both nuclear and mitochondrial disease-causing genes) presenting with a rapid regression of cognitive and motor functions, symmetrical lesions of basal ganglia at brain MRI, increased serum and CSF lactate and specific patterns at the pathological examination of muscle tissue or cultured fibroblast [27] .
Metabolic workup should be completed with urinary organic acids and plasma acylcarnitines (especially in patients with neurological derangements after acute illnesses), plasma and urinary uric acid (in patients with dystonia and self-injurious behaviors), CSF/plasma glucose ratio (in patients with seizures or movement disorders worsening during fasting) and urinary copper (in patients with movement disorders associated with signs of liver dysfunction) [4] .
Disorders with prominent involvement of brainstem and cerebellum
Ponto-cerebellar hypoplasias
Ponto-cerebellar hypoplasias include ten autosomal recessive disorders with pre-natal onset characterized by cerebellar hypoplasia/atrophy and variable degrees of pontine hypoplasia [28] . Clinical presentations include hypotonia at birth (severe in utero contractions are reported in some cases), spasticity, epilepsy, progressive microcephaly, breathing and swallowing difficulties, failure to thrive, abnormal ocular movements, developmental delay/intellectual disability and multiorgan involvement (mainly retina and skeleton) [28] . Pathogenic mutations involving CASK and TSEN 54 genes account for about 50% of the cases, while forms related to other genes such as EXOSC3, RARS2 and VLDLR are less frequent [28] . One-third of the cases are not related with known disease-causing gene mutations [28] .
Hereditary ataxias
Spinocerebellar ataxias include 45 different forms with an autosomal dominant transmission in which cerebellar degeneration is associated with a progressive loss of functions involving other structures of central or (less frequently) peripheral nervous system [29] . Clinical presentations include, according to the different subtypes, pure signs of cerebellar dysfunctions and the association of cerebellar signs with spasticity, hyper/hyporeflexia, sensory defects, dystonia or cranial nerves impairment [29] .
Friedreich ataxia is an autosomal recessive disorder due to mutations in the gene encoding for frataxin (a protein involved in iron-sulfur and heme homeostasis) and it is characterized by progressive gait and limb ataxia, limb muscle weakness, absent lower limb reflexes, dysarthria, decreased vibratory sense and proprioception, scoliosis, pes cavus, hammertoe, cardiomyopathy or pancreatic dysfunction [30] .
Ataxia telangiectasia is an autosomal recessive disorder (mutations in ATM gene) characterized by cerebellar ataxia, telangiectases, immune defects, predisposition to malignancy and abnormal sensitivity to ionizing radiation [31] .
Marinesco-Sjogren syndrome is an autosomal recessive disorder due to mutations in SIL1 gene that is characterized by cerebellar ataxia, congenital cataracts, progressive myopathic muscle weakness, and delayed psychomotor development, short stature, and hypergonadotropic hypogonadism [32] .
Disorders with prominent involvement of spinal cord, cranial and peripheral nerves
Spinal muscular atrophy
Spinal muscular atrophy (SMA) is an autosomal recessive disease with an estimated incidence of 1 in 6000 to 1 in 10,000 live births and a carrier frequency of 1/40-1/60 [33] . This disease is caused by homozygous mutations of the survival motor neuron 1 (SMN1) gene [33] . It is characterized by degeneration of alpha motor neurons in the spinal cord inducing a progressive proximal muscle weakness and paralysis [33] . Clinical phenotype is classified into four grades of severity according to the age of onset and motor function achieved [33] .
Hereditary neuropathies
Hereditary neuropathies are a heterogeneous group of rare disorders (including Charcot-Marie-Tooth variants, Refsum disease and Alstrom syndrome) that have an overall prevalence of 1 in 2500 individuals in adult while no epidemiologic data about pediatric age are available [34] . Clinical presentations include neuropathic symptoms with onset during infancy, long and slowly progressing symptoms and foot deformities (pes cavus and hammertoes) [34] .
Leber optic neuropathy
Leber optic neuropathy is the most common inherited neuropathy of cranial nerves and it is due to multiple pathogenic mutations of mitochondrial DNA [35] . Clinical features include acute or subacute central vision loss leading to central scotoma and blindness with onset in the second decade of life [35] .
Disorders with prominent involvement of skeletal muscles
The dystrophinopathies are the most common disorders associated with muscular degeneration and cover a spectrum of x-linked disease that includes Duchenne muscular dystrophy (that is rapidly progressive) and Becker muscular dystrophy (with more stable muscle function over time) [36] . Duchenne muscular dystrophy usually presents in early childhood with delays in walking independently and standing up from a supine position, proximal weakness resulting in a waddling gait and difficulty in climbing stairs, running, jumping, and standing up from a squatting position [36] . Its natural history includes a complete loss of ambulation within the age of 12 years and a cardiomyopathy after the age of 18 years [36] .
Acquired disorders
Subacute sclerosing panencephalitis occurs about 5-6 years after measles infection or vaccination and presents with psychiatric manifestation, myoclonic seizures, motor regression and akinetic mutism in the final stages [37] . The diagnosis is based on the clinical and serological evidences of a previous measles infection, on the presence of periodic complexes at EEG and areas of demyelination at brain MRI [37] . Rubella virus and HIV could result in similar chronic clinical presentations [37] . Recent studies evidenced abnormalities of white matter tracts in fronto-striatal networks in adolescent with neuroAIDS at the early stages in which an impairment of executive functions could be evident [38] . Depression, attention-deficit hyperactivity disorder, and behavioral problems could also be observed during this age range [38] .
The diagnosis of multiple sclerosis can be easier, according to the 2017 revision of Mc Donald criteria, in children older than 11 years of age in which multiple clinical attacks, neuroradiological evidences of a dissemination in time or space and CSF oligoclonal bands are reported [39] .
Rasmussen encephalitis is an immune-mediated disorders presenting with intractable seizures (prominently epilepsia partialis continua) and motor regression resulting from a progressive atrophy involving one cerebral hemisphere [40] .
The evaluation of thyroid function, eventual vitamin B12 or E deficiencies and drugs effects should be always considered for an ideal completion of diagnostic workup [2] .
Targeted treatments: current practice and future perspectives
Therapeutic strategies for pediatric neurodegenerative disorders include both traditional (old drugs, specific dietary treatments, enzyme replacement therapies) and innovative treatments (new systems of administration of old drugs, different techniques of gene therapy and hematopoietic stem cells transplantation) [2, 4] .
For several years, the treatment of these patients has been merely symptomatic [2, 4] . In the last decade, the progresses of basic and clinical research expanded the armamentarium of disease-modifying therapies and improved the prognosis of an increasing number of diseases [2, 4] .
Dietary treatments
Phenylketonuria is the prototype of the disorders that are diagnosed through neonatal screening in which an effective dietary therapy prevents clinical and neuroradiological manifestations of a leukoencephalopathy [2] . Ketogenic diet is the gold standard therapy for Glut 1 deficiency and pyruvate kinase deficiency but it can be also applied in severe drugresistant epileptic encephalopathies [4] . Other specific diets can produce transient benefits in selected diseases (reduction of phytanic acid intake in Refsum disease or VLCFA limitation in X-linked adrenoleukodystrophy) [2] .
Old and new drugs
Some traditional drugs tone down the symptoms in specific cases (i.e., allopurinol for Lesch-Nyhan disease or d-penicillamine, trientine and zinc acetate for Wilson disease) [2] . Mitochondrial encephalopathies can be treated with various molecules (including nicotinamide, riboflavin, dichloroacetate, L-carnitine or Coenzyme Q10) that offer different spectra of efficacy [2] .
Transitory benefits on neurological progression (with prominent advantages on dysphagy) can be observed with miglustat in patients affected by Niemann-Pick type C disease [2] . A promising alternative role was recently attributed to intrathecal 2-hydoxypropyl-β-cyclodextrin because of relevant results in three patients even if further data are expected from an ongoing controlled randomized trial on a larger cohort [41] .
The treatment of epileptic encephalopathies is prominently based on commercially available antiepileptic drugs with few selected indications for specific molecules (i.e., ACTH for West syndrome or stiripentol for Dravet syndrome) [11] . An aggressive antiepileptic therapy can be justified when the correlation between seizures and neurological deterioration is demonstrated while it is less useful in that encephalopathies in which developmental delay/ arrest precedes seizures onset [11] . Some metabolic epileptic encephalopathies have disease-modifying treatments that positively influence the prognosis (i.e., pyridoxine for ALDH7A1 deficiency or pyridoxal-5I-phosphate for PNPO deficiency) [4] . Anecdotal evidences of efficacy were reported for quinidine and memantine, respectively, in KCNT1 and in GRIN2D-related refractory epilepsy [42] .
Enzyme replacement therapies
Enzyme replacement therapy improved the prognosis in Pompe disease and mucopolysaccharidoses type I and VI, while promising results were recently obtained with cerliponase alpha for the treatment of ceroid lipofuscinosis type 2 [22, 43] .
New systems of administration of old drugs
An improvement in the scores of International Cooperative Ataxia Rating Scale and Vineland Adaptive Behavior Scales without evidences of steroids-associated side effects was obtained in a small cohort of patients with ataxia telangiectasia with the administration of low dosages of dexamethasone loaded to autologous erythrocytes [44, 45] .
Stem cells transplantation and gene therapy
Hematopoietic stem cells transplantation could slow down neurological deterioration in Krabbe disease or in metachromatic leukodystrophy and it was associated with increased survival rates at 5 and 10 years in early treated adrenoleukodystrophy [2, 46, 47] . An improvement of different neuroradiological markers was obtained in a phase I trial on four patients with Pelizaeus-Merzbacher disease who received an MRI-guided surgically implanted fetal-derived neural stem cells into the deep white matter [47] .
Clinical manifestations and the evolution of the disease were prevented in three pre-symptomatic patients with genetic, biochemical, and neurophysiological evidence of late infantile metachromatic leukodystrophy who were treated with a hematopoietic stem cell gene therapy mediated by a lentiviral vector [46] . A similar strategy that was based on an adenoviral vector-mediated gene delivery resulted in significant improvement of motor outcomes, survival rates and seizures frequency in patients with Canavan disease and SMA1 who received, respectively, intrathecal and intravenous injections [47] . Comparable results were observed in pre-clinical studies involving patient's fibroblasts or mutant mice with giant axonal axonopathy and mouse models of Cx47-related Pelizaeus-Merzbacher-like disease [47] [48] [49] .
A gene editing approach based on the CRISPR/Cas 9 system (a complex that is able to cut selected DNA regions and to insert the correct sequences in the targeted gene) normalized the phenotype in mouse models of Duchenne muscular dystrophy and also promoted an ex vivo correction of gene defects in patient's induced pluripotent stem cells [47] .
Other innovative strategies were recently applied to the treatment of patients with spinal muscular atrophy (nusinersen is an antisense oligonucleotide that promotes the increased synthesis of SMN1 protein) and Duchenne muscular dystrophy (ataluren enables ribosomal readthrough of premature stop codons in subjects with nonsense mutation; eteplirsen stimulates an increased synthesis of dystrophin by skipping exon 51 of the DMD gene) [50] [51] [52] . Antisense oligonucleotide-mediated suppression of the transcript for glial fibrillary acidic protein (GFAP) was also obtained through single intracerebroventricular injections in a mouse model of Alexander disease [53] . This approach resulted in an improvement of whole body condition, the reversal of Rosenthal fibers, the improvement of microglial and stressrelated markers and the rescue of hippocampal neurogenesis [53] . The same therapeutic strategy decreased the levels of CSF mutant huntingtin without serious adverse effects in a phase I/IIA dose-dependent clinical trial in patients with Huntington disease, while an increase in lifespan, motor functions and brain pathology was reported in Niemann-Pick type C mutant mice [54, 55] . An improvement in best visual activity, visual field tests, retinal nerve fiber layer thickness and visual evoked potentials was reported in three different trials including patients with Leber optic neuropathy who were treated with intravitreal injections of mitochondrial NADH-ubiquinone oxidoreductase chain 4 (ND4) gene transported by adenoviral vectors [56] .
Conclusions
Neurodegenerative disorders with onset in childhood include a heterogeneous group of diseases that require a multidisciplinary approach and management in each phase of their natural history. The growing potentialities of genetic discoveries and the relevant perspectives offered by new tailored treatments will allow in the future a substantial improvement of the poor prognosis that is generally typical of these diseases. These aspects highlight the importance of an early diagnostic characterization through making physician's involved in care more aware of these possibilities and features.
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